Pharma Copay Program Vendors: ConnectiveRx vs Valeris vs Phil vs Apollo Care

Overview

Pharma copay program vendors now compete across card processing, accumulator and maximizer detection, digital enrollment, affordability routing, and gross-to-net analytics. Copay and financial assistance is the single largest patient-facing line item in most specialty brand budgets. The U.S. pharmaceutical industry spends an estimated $17 to $20 billion annually on copay cards and patient assistance programs, and the market sits at an inflection point in 2026. Three forces are simultaneously reshaping vendor selection: the IRA’s Medicare Part D redesign, the continued spread of commercial copay accumulators and maximizers, and a generational shift from per-redemption card processors to digital-first orchestration platforms.

The Part D $2,000 out-of-pocket cap (indexed to $2,100 in 2026) has cut manufacturer per-patient copay card exposure by 60 to 85% for Medicare beneficiaries, but it has not shrunk copay budgets; it has reallocated them. The new Manufacturer Discount Program imposes a 10% discount in the initial coverage phase and a 20% discount in the catastrophic phase, obligations that previously did not exist. For a $200,000 specialty drug, MDP alone runs roughly $21,000 per patient annually, more than offsetting the copay card savings. Commercial copay, meanwhile, remains the active battleground: roughly 50 to 60% of commercial lives are covered by plans running accumulators or maximizers, and only 26 states (representing 17% of the commercial market) have passed anti-accumulator protections.

Against this backdrop, four vendors compete for the manufacturer copay processing contract. ConnectiveRx is the incumbent high-volume processor with the only publicly documented unit economics. Valeris is the 2025-consolidated platform inheriting TrialCard’s nine accumulator patents and PharmaCord’s pharmacy infrastructure. Phil is the digital-native challenger running shared-outcome economics. Apollo Care is the emerging Flexpoint Ford-backed roll-up positioning around gross-to-net optimization. This comparison is a direct sibling to our Hub Services Platforms comparison; where that piece focuses on case management and benefit verification, this one focuses specifically on the copay transaction layer.

---

Competitor Profiles

ConnectiveRx

Headquartered in Whippany, NJ. Founded around 2005 and recapitalized by Genstar Capital in 2020. The largest publicly documented copay processor by revenue concentration, with the copay segment estimated around $116 million, or approximately 27% of total revenue. Total company revenue sits in a $280 to $680 million range reflecting conflicting sources. Serves 140+ manufacturers and 550+ brands with roughly 1,700 to 1,800 employees. Copay revenue is concentrated in transaction and monthly management fees, with cash-claims programs also contributing to the segment. Launched ConnectiveRx Pharmacy in September 2025 for direct-to-patient dispensing.

Valeris

Valeris is the 2025-merged platform combining TrialCard, Mercalis, and related assets under Permira (majority) and Odyssey (minority) ownership. Dual-headquartered in Morrisville, NC and Jeffersonville, IN. TrialCard’s heritage dates to 2000 as the original copay card pioneer, and the company holds nine U.S. patents covering copay and accumulator detection methodologies. Post-merger employee count runs 2,500 to 3,500 with estimated revenue of $400 to $800 million. Reports 500+ clients, 275+ brands, and historical benefits processed exceeding $1 billion per year under the TrialCard era. Owns PharmaCord’s non-commercial pharmacy infrastructure (600 dispenses per hour, 99.999% accuracy, serialized track-and-trace) across Louisville, Scottsdale, and North Carolina sites. Policy Reporter, the integrated payer intelligence SaaS, operates as a standalone revenue line growing over 20% year-over-year.

Phil

Founded 2015, headquartered in San Francisco, CA. VC-backed (Warburg Pincus, GreatPoint Ventures, others) with a $50 million debt facility from K2 HealthVentures disclosed July 2025. Approximately 288 employees. Revenue undisclosed (Growjo estimates roughly $35 million, but likely higher given reported 150%+ growth). Runs approximately 35 manufacturer programs as a digital-first access orchestration platform spanning 50 states with 98% plan coverage. Operates an algorithmic pharmacy routing model across chain, independent, and specialty pharmacies, with partner pharmacies participating via Western Wellness Solutions wholesale at roughly $12 per script dispensing fee. PHIL Direct extends the platform to direct-to-patient models. Copay assistance is embedded as an integrated access layer rather than sold as a standalone product.

Apollo Care

Headquartered in Chicago, IL, founded circa 2015 with Flexpoint Ford holding a minority PE position. Employee count in the 51 to 200 range. Revenue undisclosed. Emerging platform focused on gross-to-net optimization and analytics-driven copay design. Has built capability through a rapid acquisition trajectory: eStrat (copay provider), Scripts Rx (pharmacy platform), and Truveris Life Sciences, each folded into the Apollo Care stack. Positions as a tech-first alternative to legacy processors, with advanced copay products, Hub Lite services, and integrated GTN solutions. Manufacturer client list not publicly detailed, reflecting earlier-stage market presence.

---

Head-to-Head Comparison

Transaction Model and Pricing

Dimension	ConnectiveRx	Valeris	Phil	Apollo Care
Copay pricing	~$2.50 per redemption at scale; 69% transaction fees, 25% monthly management	Bundled platform pricing; TrialCard-era per-redemption plus management fees	Shared-outcome / per-dispense model aligned with manufacturer results	Per-claim plus advanced copay models with GTN integration
Gross margin	71% copay gross margin; 57% contribution margin; 55% FCF margin	Not publicly disclosed; platform bundling obscures segment margins	Not publicly disclosed; claims operations at ~1/10th cost of traditional hubs	Not publicly disclosed
Contract structure	Copay: shorter-cycle transactional; Hub: 3-year terms	Multi-service platform MSAs; inherited TrialCard and PharmaCord contracts	Shared-outcome economics; 6-week launch timelines	Brand-level program contracts
Cash claims share	29% of copay revenue (pre-insurance subsidy)	Bridge and free-goods programs available	Bridge programs integrated into access workflow	Not documented
Retention	96% gross retention on copay segment	Not publicly disclosed	Not publicly disclosed	Not publicly disclosed

Verdict: ConnectiveRx provides unusually visible unit-economics benchmarks for a private copay processor, but buyers should treat those figures as approximate for 2026 because no competitor has released comparable detail. Valeris bundles copay into a broader Insights + Patient Support platform, which creates procurement friction: buyers who want only the copay processor function must insist on unbundled line-item pricing. Phil’s shared-outcome design aligns vendor incentives with manufacturer performance and claims a structural cost advantage, but it makes apples-to-apples benchmarking difficult. Apollo Care is the least transparent on unit cost given its scale.

Pharmacy Network Reach

Dimension	ConnectiveRx	Valeris	Phil	Apollo Care
Network type	EHR-integrated prescriber network (1.2M HCPs); processes through existing pharmacy POS	Multi-site non-commercial pharmacy network (Louisville, Scottsdale, NC); partner pharmacies	50-state retail/chain/specialty pharmacy network; 98% plan coverage; controlled routing	Scripts Rx (acquired pharmacy platform)
Dispensing capability	ConnectiveRx Pharmacy launched Sept 2025 (DTP); historically pharmacy-agnostic	PharmaCord non-commercial pharmacy — 600 dispenses/hour, 99.999% accuracy, serialized track-and-trace	Algorithmic routing to payer-contracted pharmacies; partner pharmacies receive ~$12/script dispensing fee via WWS wholesale	Scripts Rx platform (details limited)
National chain coverage	Processes through all major chain POS systems	National coverage via hub routing and direct pharmacy network	Chain, independent, and specialty across all 50 states	Not documented
Specialty pharmacy	New DTP pharmacy; historically routed to external SP partners	Integrated SP via PharmaCord infrastructure	Limited today; specialty-lite focus; expanding	Limited documentation

Verdict: Phil’s algorithmic pharmacy routing is the most architecturally novel model in the category — the platform steers each prescription to the optimally contracted pharmacy rather than letting the patient or prescriber pick, and partner pharmacies participate economically through Western Wellness Solutions. That design produces measurably higher dispense rates and better copay alignment. ConnectiveRx has the broadest prescriber activation network at roughly 1.2 million HCPs engaged through EHR workflows, which is a copay pull-through asset rather than a dispensing asset. Valeris owns the most sophisticated non-commercial pharmacy infrastructure via PharmaCord, useful for bridge and free-goods programs. Apollo Care’s Scripts Rx acquisition is too recent to evaluate at scale.

Accumulator and Maximizer Detection

Dimension	ConnectiveRx	Valeris	Phil	Apollo Care
Accumulator detection	Operational capability documented; specific detection methodology not publicly detailed	Industry-leading. 9 U.S. patents from TrialCard era; TC Synapse fraud/accumulator detection; TrialCard Pay for Medicaid Best Price compliance	Platform detects and adjusts assistance based on coverage status; specific tooling not publicly detailed	Advanced copay product implies capability; specifics not documented
Maximizer detection	Not specifically documented	First-in-market medical benefit maximizer detection via Policy Reporter (Feb 2026); identified 200+ brands targeted	Not specifically documented	Not specifically documented
Published accumulator economics	None publicly released	5% of patients in accumulator programs consume 40% of manufacturer benefit at ~$18K/patient	None publicly released	None publicly released
Indirect mitigation strategy	TrueConnect dynamic copay logic (historical ConnectiveRx product)	Full accumulator IP stack plus payer intelligence	Asymmetric copay pricing — lower copay through PhilRx vs. retail	Not documented

Verdict: Valeris is the clear category leader on accumulator and maximizer protection, and it is probably the single most defensible differentiator in this entire comparison. The stack combines nine patents, TC Synapse fraud detection, TrialCard Pay for Best Price compliance, and the February 2026 first-in-market medical benefit maximizer detection via Policy Reporter. For manufacturers whose commercial copay programs are bleeding to payer arbitrage — and that is most of them, given that roughly 50 to 60% of commercial lives are in accumulator or maximizer plans — Valeris is the default choice. Our primer on copay accumulators and maximizers outlines the economic mechanics in more detail. ConnectiveRx’s TrueConnect product predates the Valeris consolidation and remains operational, but the IP depth is thinner. Phil’s indirect workaround — pricing PhilRx below retail to reduce the attack surface — is clever but not a substitute for real-time adjudication-layer detection. Apollo Care’s capabilities are undocumented.

Digital vs. Traditional Architecture

Dimension	ConnectiveRx	Valeris	Phil	Apollo Care
Architecture	Tech-enabled call center + EHR messaging network; EDW and hub CRM re-platform underway	Salesforce Health Cloud CRM (CLS) + PharmaCord Lynk; AI contact center; IDP cut processing time ~40%	Digital-first: SMS enrollment, no app download, EHR-embedded pharmacy option; <5% of patients require a phone call	Purpose-built technology platforms; tech-first approach
eVoucher / digital card	Copay card via pharmacy POS integration	PatientLink digital self-serve designed to shift 80%+ of copay calls to digital; QuickPath API	Digital-native: copay applied automatically in access workflow; no physical cards needed	Digital copay and analytics tools
Patient enrollment	Hub portal + call center; A&A messaging reaches patients via EHR and pharmacy workflows	Multi-channel: call center, PatientLink digital portal, eServices suite	SMS on mobile browser, EHR-prefilled, under 2 minutes; 80-90% enrollment rates	Digital enrollment via platform
Launch timeline	Standard hub: months; copay programs: weeks	Standard platform deployment	~6 weeks post-contract	Not documented

Verdict: Phil is the most digital-native platform and the only one with documented consumer-grade onboarding metrics (80 to 90% enrollment conversion, sub-two-minute registration, roughly six-week launches). That is a generational gap versus traditional hub-plus-card processors and matters materially for early-stage brands where rapid enrollment ramp is the primary commercial objective. Valeris is investing aggressively in digital — PatientLink is designed to shift 80%+ of copay calls away from humans, and intelligent document processing has already compressed processing time ~40% — but carries legacy infrastructure from the three merged companies. ConnectiveRx’s strength is the prescriber-facing EHR messaging network, not patient-facing digital enrollment. Apollo Care positions as tech-first but publishes few proof points.

Manufacturer Reporting and Analytics

Dimension	ConnectiveRx	Valeris	Phil	Apollo Care
Real-time analytics	Enterprise Data Warehouse under development ($2.9M capex 2022, $4.0M 2023); cross-segment hub/copay/A&A visibility	Policy Reporter: real-time formulary, coverage, PA, and OOP tracking across hundreds of payers. TC Catalyst integrated analytics	Script-level visibility: enrollment rates, PA approvals, drop-off points, copay distribution, refill cadence, adherence	Data warehousing plus integrated GTN solutions
Patient journey tracking	Cross-segment — prescriber A&A through hub enrollment through copay redemption	End-to-end: pre-approval market access through dispensing and adherence	Full prescription lifecycle from EHR prescribing through enrollment, PA, dispensing, refill	Patient access analytics (limited detail)
ROI dashboards	Copay ROI well-benchmarked (71% gross margin, $2.50/redemption)	Multi-dimensional: payer intelligence, program performance, patient outcomes	Program Dashboard with territory, HCP, and order-level visibility	GTN optimization analytics
Payer intelligence	Limited	Strongest. Policy Reporter is a standalone SaaS product >20% YoY revenue growth	Payer coverage integrated into routing, not a standalone intelligence product	Not documented

Verdict: Valeris leads on payer intelligence. Policy Reporter is a freestanding SaaS product growing over 20% year-over-year, not a feature, and it feeds directly into copay program design decisions (formulary changes, tier movement, PA requirements, plan OOP). Phil leads on real-time prescription journey analytics, with territory- and order-level visibility that manufacturers’ own data warehouses typically cannot produce. ConnectiveRx’s latent asset is the cross-segment data combination (prescriber A&A messaging + hub enrollment + copay redemption) that, when the EDW build completes, will be uniquely comprehensive — though as of early 2026, it is not yet operationally accessible to manufacturer clients. Apollo Care emphasizes GTN integration as a differentiator but public documentation is thin.

IRA and Part D Readiness

Dimension	ConnectiveRx	Valeris	Phil	Apollo Care
Part D redesign readiness	Copay economics will shift as the $2,000 OOP cap and MDP phase take effect; 22% of 2022 revenue from LOE-exposed drugs	TrialCard Pay directly addresses Medicaid Best Price compliance; Policy Reporter tracks Part D formulary in real time	PHIL Direct positions for DTP models where Part D dynamics reshape manufacturer economics	GTN optimization capabilities suggest adaptability
Medicare GLP-1 coverage	Novo Nordisk programs benefit from mid-2026 Medicare GLP-1 obesity coverage ($50/month copay cap; $245/month injectable pricing)	Payer intelligence tracks Medicare coverage changes; hub infrastructure supports Medicare GLP-1 access	Not specifically documented for Medicare populations	Not documented
Semaglutide IRA pricing	Directly impacted: Novo Nordisk (largest client) faces 71% price discount to $274/month for semaglutide in Part D effective January 2027	Policy Reporter will track negotiated price implementation; copay economics change materially for Medicare semaglutide	Indirect exposure; more commercial-channel relevant	Not documented
M3P navigation capability	Must build; leverages cross-segment data	Platform supports multi-pathway financial navigation	Can integrate into access orchestration workflow	Not specifically documented

Verdict: Valeris is best positioned to navigate IRA and Part D changes through Policy Reporter’s real-time payer tracking and TrialCard Pay’s Best Price compliance tool. ConnectiveRx faces the most direct IRA exposure given Novo Nordisk as its largest client and semaglutide’s selection for Part D negotiation — that is a concentration risk worth underwriting in any vendor diligence. Phil and Apollo Care are more commercially focused, which insulates them from direct Medicare negotiation exposure but also limits Part D upside. For context on how Part D redesign rewrites manufacturer copay budgets (copay card spend down 60 to 85% per Medicare patient, MDP obligations now $4,200 to $56,000 per patient depending on drug price), see the broader hub services market analysis.

Integration and EHR Reach

Dimension	ConnectiveRx	Valeris	Phil	Apollo Care
EHR integration	Deepest: 1.2M prescribers in clinical workflows via Veradigm, Athena Health, Epic-connected systems	QuickPath API with real-time EHR/e-prescribing integration; eServices suite (eBV, ePA)	PhilRx appears as retail pharmacy option in EMRs; CoverMyMeds PA integration	Limited documentation
Hub connectivity	Core hub + copay integration; cross-segment data flow	Fully integrated hub within platform (PharmaCord + Mercalis capabilities)	Hub services built into platform natively; not a bolt-on	Hub Lite services available
Pharmacy POS	Processes through pharmacy POS for copay card redemption	PharmaCord non-commercial pharmacy POS; partner pharmacy network	Algorithmic pharmacy routing; partners connected via WWS wholesale	Scripts Rx pharmacy platform

---

Use Case Recommendations

Choose ConnectiveRx when:

• You need the proven high-volume copay processor with documented economics. The $2.50-per-redemption benchmark, 71% gross margin, and 96% gross retention demonstrate operational maturity and give procurement a real reference point.
• Prescriber activation matters as much as copay execution. The 1.2 million HCP network engaged through EHR workflows is a top-of-funnel acquisition engine that feeds copay enrollment — no competitor in this set has a comparable prescriber footprint.
• Cross-segment hub + copay + A&A intelligence is the strategic goal. Once the EDW build is complete, the combined data asset will produce patient journey visibility no single competitor can match today.
• Your program has significant commercial and Medicare mix. ConnectiveRx’s cash claims subsidy model (29% of copay revenue) and its scale give it the operational bandwidth to run both channels simultaneously.

Weakness callout: Novo Nordisk concentration risk is real. Semaglutide’s 71% Part D price cut in January 2027 will test ConnectiveRx’s revenue base directly. Technology self-disclosure is also thinner than peers; the EDW is still being built. Accumulator IP is less documented than Valeris’s.

Choose Valeris when:

• Accumulator and maximizer exposure is the single biggest copay pain point. Nine TrialCard patents, TC Synapse, TrialCard Pay, and the first-in-market medical benefit maximizer detection via Policy Reporter make this the definitive choice. Published economics: 5% of accumulator-program patients consuming 40% of manufacturer benefit at ~$18,000 per head.
• Real-time payer intelligence should inform copay design. Policy Reporter tracks formulary, coverage policies, PA requirements, and OOP costs across hundreds of payers in real time — the only standalone SaaS product of its kind in this comparison.
• You want one platform from market access strategy through copay execution. The integrated Insights + Patient Support + HCP Engagement + Pharmacy stack reduces vendor coordination overhead for complex commercial launches.
• IRA compliance and Medicaid Best Price risk management are board-level concerns. TrialCard Pay is the only purpose-built Best Price compliance tool among these four vendors.

Weakness callout: Platform bundling obscures copay unit economics. Buyers must demand unbundled pricing or risk overpaying for adjacent services. Legacy infrastructure from three merged companies (TrialCard, Mercalis, PharmaCord) is still being harmonized. Segment-level copay margin structure is undisclosed, making TCO modeling harder than with ConnectiveRx.

Choose Phil when:

• You need the fastest launch in the category. Six weeks from contract to live, 80 to 90% enrollment rates, sub-two-minute SMS onboarding — these are the structural advantages of a digital-first architecture over legacy call-center-plus-card models.
• Prescription conversion and covered dispenses matter more than card redemption volume. Phil’s asymmetric copay pricing (PhilRx lower than retail) aligns copay with hub enrollment rather than treating it as a separate transaction.
• You are a specialty-lite or GLP-1 brand with limited commercial infrastructure. Phil’s all-in-one design — enrollment, PA, pharmacy routing, copay, refill — removes the integration burden emerging brands typically face when wiring together three or four vendors.
• Algorithmic pharmacy routing is a strategic fit. The Western Wellness Solutions wholesale model means partner pharmacies are economically aligned with manufacturer program performance, not just dispense volume.

Weakness callout: Specialty pharmacy depth is limited compared to Valeris (PharmaCord) or ConnectiveRx (ConnectiveRx Pharmacy). Accumulator and maximizer tooling is indirect (via pricing asymmetry) rather than adjudication-layer detection. Revenue scale and client count (~35 programs) are materially smaller than the other three — a risk factor for large-brand procurement teams worried about partner durability. Medicare exposure is limited; manufacturers with heavy Part D mix will not get full leverage from the platform.

Choose Apollo Care when:

• Gross-to-net optimization is the primary copay objective. Apollo Care’s positioning around integrated GTN solutions signals deeper alignment with finance-led copay strategies — ideal for CFO-sponsored programs rather than commercial-sponsored programs.
• You want an emerging partner with PE backing and rapid capability build. The eStrat copay acquisition, Scripts Rx pharmacy acquisition, and Truveris Life Sciences pickup signal aggressive roll-up by Flexpoint Ford.
• Pricing flexibility matters more than scale certainty. Smaller players typically offer more attentive service and negotiable terms than larger incumbents.
• You are piloting a secondary copay program and want a tech-forward alternative to ConnectiveRx or Valeris. Apollo Care fits well as a second source in dual-vendor strategies.

Weakness callout: Public documentation is materially thinner than the other three vendors. Manufacturer client list, copay program scale, transaction volume, accumulator capabilities, and unit economics are largely undisclosed. This is an execution-risk vendor until more operational data is visible. Scripts Rx integration is too recent to evaluate at scale.

---

Key Decision Factors

If your priority is…	Choose…
Transparent per-unit copay economics	ConnectiveRx ($2.50/redemption benchmark, 71% gross margin)
Accumulator and maximizer protection	Valeris (9 patents, TC Synapse, Policy Reporter maximizer detection)
Digital-first, highest enrollment rates	Phil (80-90% enrollment, 6-week launch)
GTN-integrated copay analytics	Apollo Care (finance-led program design)
Prescriber network + copay bundled	ConnectiveRx (1.2M HCPs in EHR workflows)
Payer intelligence informing copay design	Valeris (Policy Reporter standalone SaaS)
Speed to launch (<6 weeks)	Phil (SMS enrollment, digital-native)
Part D and IRA compliance readiness	Valeris (TrialCard Pay, Best Price compliance)
Owned non-commercial pharmacy for bridge/PAP	Valeris (PharmaCord: 600 dispenses/hour)
Algorithmic pharmacy routing	Phil (WWS wholesale partnership model)
Second source / dual-vendor strategy	Apollo Care (emerging, attentive, flexible)
Cross-segment (hub + copay + A&A) data	ConnectiveRx (once EDW build completes)

---

Verdict

ConnectiveRx remains the default institutional choice for copay processing at scale. The $2.50 per redemption benchmark and 71% gross margin give buyers a hard reference point no competitor has matched on transparency. The 1.2 million HCP prescriber network is a real top-of-funnel differentiator. The risk to underwrite is Novo Nordisk concentration: semaglutide’s 71% Part D price discount effective January 2027 will compress the largest revenue base in the book, and IRA adaptation is the company’s single biggest operational test.

Valeris is the definitive choice when accumulator, maximizer, or payer-intelligence exposure is the driving decision factor. Nine TrialCard patents, TC Synapse, TrialCard Pay’s Best Price compliance, and Policy Reporter’s February 2026 medical benefit maximizer detection make the accumulator/maximizer protection stack the deepest in the category. For manufacturers with heavy commercial mix, significant accumulator-program exposure, or IRA/Medicaid compliance concerns, Valeris has the cleanest case. Procurement should insist on unbundled copay line-item pricing given the platform bundling.

Phil is the correct answer for digital-first, speed-to-launch, enrollment-optimized programs. Six-week launches, 80 to 90% enrollment conversion, and algorithmic pharmacy routing are genuine architectural advantages over legacy processors. Phil fits best when copay is an integrated layer of an access orchestration platform rather than a standalone card program. It is less suited to mature brands with heavy Medicare mix or those demanding adjudication-layer accumulator detection.

Apollo Care is a credible fourth option — most interesting for GTN-driven program design, dual-vendor strategies, or buyers willing to bet on an emerging PE-backed roll-up with Flexpoint Ford sponsorship. Public documentation remains thin, and buyers should weight execution risk accordingly. For a primary copay processor at a major brand, the other three are more proven today.

Practical note: Most manufacturers no longer run a single copay vendor across the portfolio. The emerging norm is payer-type segmentation (one vendor for commercial copay, another for Medicare M3P navigation and foundation routing) and brand-level vendor selection based on each asset’s accumulator exposure, speed-to-launch pressure, and digital enrollment requirements. That reality makes the “pick one processor” framing less accurate than it was even two years ago. For a structured RFP approach, see our hub RFP framework.

---

Related Reading

Vendor Profiles

• ConnectiveRx
• Valeris
• Phil
• Apollo Care

Category Pages

• Copay & Financial Assistance
• Hub Services
• Specialty Pharmacies

Related Comparisons and Analyses

• Hub Services Platforms: ConnectiveRx vs AssistRx vs CareMetx vs EVERSANA — Hub case management and BV/PA comparison
• ConnectiveRx profile — Hub and copay operating profile
• Hub Services Buyer’s Guide — Vendor selection framework
• Hub RFP Framework — Structured procurement approach
• Big 3 PBM Specialty Pharmacies — Downstream dispensing channel context

---

Comparison compiled April 2026. Confidence: medium. Apollo Care documentation is thinner than the other three vendors, and specific financial metrics for Valeris’s copay segment are obscured by platform bundling. ConnectiveRx unit-economics benchmarks should be treated as directional; current 2026 figures may differ. All outcomes metrics (enrollment rates, margins, processing speeds) are vendor-published and not independently audited.